Temozolomide
Active ingredient: Temozolomide
In short: Temozolomide Capsules are indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. Temozolomide capsules are indicated for the: • adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; • treatment o
What is Temozolomide used for?
Temozolomide Capsules are indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment.
Temozolomide capsules are indicated for the:
• adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma;
• treatment of adults with refractory anaplastic astrocytoma.
Temozolomide dosage
Prior to dosing, withhold Temozolomide until patients have an absolute neutrophil count (ANC) of 1.5 x 109/L or greater and a platelet count of 100 x 109/L or greater.
For concomitant radiotherapy, obtain a complete blood count prior to initiation of treatment and weekly during treatment.
For the 28-day treatment cycles, obtain a complete blood count prior to treatment on Day 1 and on Day 22 of each cycle. Perform complete blood counts weekly until recovery if the ANC falls below 1.5 x 109/L and the platelet count falls below 100 x 109/L.
For concomitant use with focal radiotherapy, obtain a complete blood count weekly and as clinically indicated.
Administer Temozolomide once daily for 42 to 49 consecutive days during the concomitant use phase with focal radiotherapy and then once daily on Days 1 to 5 of each 28-day cycle for 6 cycles during the maintenance use phase.
Provide Pneumocystis pneumonia (PCP) prophylaxis during the concomitant use phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less .
Concomitant Use Phase:
The recommended dosage of Temozolomide is 75 mg/ m2 once daily for 42 days to 49 days in combination with focal radiotherapy. Focal radiotherapy includes the tumor bed or resection site with a 2 to 3 cm margin.
Other administration schedules have been used.
Obtain a complete blood count weekly. The recommended dosage modifications due to adverse reactions during concomitant use phase are provided in
Table 1.
TABLE 1:Dosage Modifications Due to Adverse Reactions During Concomitant Use Phase
Adverse Reaction | Interruption | Discontinuation
Absolute Neutrophil Count | Withhold Temozolomide if ANC is greater than or equal to 0.5 x 10
9/L and less than 1.5 x 10
9/L.
Resume Temozolomide at the same dose when ANC is greater than or equal to 1.5 x 10
9/L. | Discontinue Temozolomide if ANC count is less than 0.5 x 10
9/L.
Platelet Count | Withhold Temozolomide if platelet count is greater than or equal to 10 x 10
9/L and less than 100 x 10
9/L.
Resume Temozolomide at the same dose when platelet count is greater than or equal to 100 x 10
9/L. | Discontinue Temozolomide if platelet count is less than 10 x 10
9/L.
Non-hematological Adverse Reaction (except for alopecia, nausea, vomiting) | Withhold Temozolomide if Grade 2 adverse reaction occurs.
Resume Temozolomide at the same dose when resolution to Grade 1 or less. | Discontinue Temozolomide if Grade 3 or 4 adverse reaction occurs.
Single Agent Maintenance Use Phase:
Beginning 4 weeks after concomitant use phase completion, administer Temozolomide once daily on Days 1 to 5 of each 28-day cycle for 6 cycles. The recommended dosage of Temozolomide in the maintenance use phase is:
• Cycle 1: 150 mg/ m2 per day on days 1 to 5. …
How to take Temozolomide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Myelosuppression
Inform patients that Temozolomide can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, or other signs of infection
.
Hepatotoxicity
Advise patients of the increased risk of hepatotoxicity and to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity. Inform patients that they will have periodic liver enzyme tests during treatment and following the last dose of Temozolomide
.
Pneumocystis Pneumonia
Advise patients of the increased risk of Pneumocystis pneumonia and to contact their healthcare provider immediately for new or worsening pulmonary symptoms. Inform patients that prophylaxis for Pneumocystis pneumonia may be needed
.
Secondary Malignancies
Advise patients of the increased risk of myelodysplastic syndrome and secondary malignancies
.
Exposure to Opened Capsules
Advise patient to not open, chew, or dissolve the capsules. …
Warnings & precautions
Do not take this medicine if: Temozolomide is contraindicated in patients with a history of serious hypersensitivity reactions to:
• temozolomide or any other ingredients in Temozolomide capsules; and
• dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide.
Reactions to Temozolomide have included anaphylaxis
.
Myelosuppression, including pancytopenia, leukopenia and anemia, some with fatal outcomes, have occurred with Temozolomide
.
In MK-7365-006, myelosuppression usually occurred during the first few cycles of therapy and was generally not cumulative. The median nadirs occurred at 26 days for platelets (range: 21 to 40 days) and 28 days for neutrophils (range: 1 to 44 days). Approximately 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.
Obtain a complete blood count and monitor ANC and platelet counts before initiation of treatment and as clinically indicated during treatment. When TEMOZOLOMIDE is used in combination with radiotherapy, obtain a complete blood count prior to initiation of treatment, weekly during treatment, and as clinically indicated
.
For severe myelosuppression, withhold TEMOZOLOMIDE and then resume at same or reduced dose, or permanently discontinue, based on occurrence
.
Fatal and severe hepatotoxicity have been reported in patients receiving temozolomide. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide.
Pneumocystis pneumonia (PCP) has been reported in patients receiving Temozolomide. …
Temozolomide side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Myelosuppression
.
• Hepatotoxicity
.
• Pneumocystis Pneumonia
.
• Secondary Malignancies
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Newly Diagnosed Glioblastoma
The safety of Temozolomide was evaluated in study MK-7365-051
.
Severe or life-threatening adverse reactions occurred in 49% of patients treated with Temozolomide; the most common were fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia (5%).
The most common adverse reactions (≥20%) in patients treated with Temozolomide were alopecia, fatigue, nausea, anorexia, headache, constipation and vomiting.
Table 3 summarizes the adverse reactions in MK-7365-051. …
About this medicine
Temozolomide Capsules, USP are an alkylating drug. The chemical name of temozolomide, USP is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide. The structural formula of temozolomide, USP is:
The material is a white to light tan/light pink powder with a molecular formula of C
6H
6N
6O
2 and a molecular weight of 194.15. The molecule is stable at acidic pH (<5) and labile at pH >7; hence temozolomide, USP can be administered orally. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.
Temozolomide Capsules, USP:
Temozolomide capsules, USP for oral use contain either 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg of temozolomide. The inactive ingredients are as follows:
Temozolomide Capsules 5 mg:lactose anhydrous (62.17 mg), colloidal silicon dioxide (0.33 mg), sodium starch glycolate (3.75 mg), tartaric acid (1.5 mg) and stearic acid (2.25 mg). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 28fae355-e29a-4f76-9c83-bc44663ff7d4. Read the full official label on DailyMed.